- Home
- TXO vs ALLO Comparison
TXO vs ALLO Comparison
Compare TXO & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TXO | ALLO |
|---|---|---|
| Founded | 2012 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 691.6M | 707.6M |
| IPO Year | 2022 | 2018 |
Fundamental Metrics
Financial Performance| Metric | TXO | ALLO |
|---|---|---|
| Price | $13.44 | $1.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 15 |
| Target Price | ★ $20.50 | $8.35 |
| AVG Volume (30 Days) | 296.8K | ★ 6.7M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 13.57% | N/A |
| EPS Growth | N/A | ★ 34.09 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $401,012,000.00 | N/A |
| Revenue This Year | $17.21 | N/A |
| Revenue Next Year | N/A | $142,416.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 41.80 | N/A |
| 52 Week Low | $10.12 | $0.99 |
| 52 Week High | $16.15 | $4.46 |
Technical Indicators
Market Signals| Indicator | TXO | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 55.75 | 39.25 |
| Support Level | $12.89 | $1.85 |
| Resistance Level | $13.98 | $1.92 |
| Average True Range (ATR) | 0.56 | 0.12 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 52.38 | 16.67 |
Price Performance
Historical ComparisonAbout TXO TXO Partners L.P.
TXO Partners LP is focused on the acquisition, development, optimization, and exploitation of oil, natural gas, and natural gas liquid reserves in North America. Its operations focus on enhancing the development and operation of producing properties through its concentration on efficiency and optimizing exploitation of current wells.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).